Amarin (AMRN)
(Delayed Data from NSDQ)
$0.63 USD
-0.03 (-4.29%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $0.62 -0.01 (-1.20%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Brokerage Reports
0 items in cart
Amarin Corporation PLC [AMRN]
Reports for Purchase
Showing records 181 - 200 ( 363 total )
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Healthcare - Earnings Recap: Halftime Show of Our Most In-Depth, Differentiated Earnings Yet
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
With FDA AdCom in Sight, We Identify EMDAC Trends Supportive of Vascepa Progress.
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
3Q19 - All of the Hot Topics for AdCom Reviewed in Our Report
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Trick or Treat ahead of AHA: Treat With Our Day-by Day Calendar
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
An Ounce of Preparation Is Worth a Pound of Cure
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Healthcare - Earnings Recap: The More Analysis, The Merrier, Especially When Data-Driven
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Management Doesn?t Skip a Beat, As Vascepa AdCom Is Announced; Reit Buy and $51 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Vascepa Launch in Infancy, Pivotal Events on Near- Term Horizon, in Our View; Reit Buy and $51 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A